急性間欠性ポルフィリン症の市場規模、シェア、成長分析、診断別、治療別、エンドユーザー別、地域別-2025～2032年産業予測

急性間欠性ポルフィリン症市場規模は2023年に43億2,000万米ドルと評価され、2024年の44億5,000万米ドルから2032年には56億9,000万米ドルに成長し、予測期間（2025～2032年）のCAGRは3.1％で成長する展望です。

急性間欠性ポルフィリン症（AIP）市場は、認知度の向上、診断法の進歩、革新的な治療法の開発により、大きな成長を遂げています。ヘム合成に影響を及ぼすこの稀な遺伝性疾患は、医療セグメントで牽引役となっています。遺伝子検査などの診断能力の向上により、AIP症例の早期かつ正確な特定が可能となっています。さらに、製薬産業は新規治療法の研究開発に注力する一方、患者教育の向上が症状の効果的な管理に役立っています。このような進歩にもかかわらず、過小診断や限られた治療選択肢といった課題は依然として残っています。AIP市場の複雑さを乗り越え、患者の転帰を改善するためには、医療専門家、調査研究者、製薬企業の協力的なアプローチが不可欠です。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の展望
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と展望

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主要市場の考察

• 重要成功要因
• 競合の程度
• 主要投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制分析

急性間欠性ポルフィリン症市場規模：診断別&CAGR（2025～2032年）

• 市場概要
• 血液検査
• 尿検査
• DNA検査
• 血清検査

急性間欠性ポルフィリン症市場規模：治療別&CAGR（2025～2032年）

• 市場概要
• ゴナドトロピン放出ホルモン類似体
• 予防的ヘマチン注入

急性間欠性ポルフィリン症市場規模：エンドユーザー別&CAGR（2025～2032年）

• 市場概要
• 病院
• クリニック
• 研究センター

急性間欠性ポルフィリン症市場規模&CAGR（2025～2032年）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他の欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他のアジア太平洋
• ラテンアメリカ
  • ブラジル
  • その他のラテンアメリカ
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他の中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主要市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022～2024年）

    主要企業プロファイル

    • Alnylam Pharmaceuticals（米国）
    • Recordati S.p.A.（イタリア）
    • Sanofi S.A.（フランス）
    • BioMarin Pharmaceutical Inc.（米国）
    • Siemens Healthineers AG（ドイツ）
    • F. Hoffmann-La Roche Ltd（スイス）
    • Takeda Pharmaceutical Company Limited（日本）
    • Ipsen Pharma（フランス）
    • Clinuvel Pharmaceuticals Ltd（オーストラリア）
    • Quest Diagnostics（米国）
    • Mayo Clinic Laboratories（米国）
    • Bachem Holding AG（スイス）
    • Grifols, S.A.（スペイン）
    • Ferring Pharmaceuticals（スイス）
    • Sun Pharmaceutical Industries Ltd.（インド）
    • Moderna, Inc.（米国）
    • Dicerna Pharmaceuticals, Inc.（米国）
    • Zambon S.p.A.（イタリア）
    • Luitpold Pharmaceuticals, Inc.（米国）
    • Vifor Pharma（スイス）

結論と提言

Acute Intermittent Porphyria Market size was valued at USD 4.32 billion in 2023 and is poised to grow from USD 4.45 billion in 2024 to USD 5.69 billion by 2032, growing at a CAGR of 3.1% during the forecast period (2025-2032).

The Acute Intermittent Porphyria (AIP) market is experiencing significant growth due to increased awareness, advancements in diagnostics, and the development of innovative treatment options. This rare genetic disorder, which affects heme synthesis, is gaining traction in the healthcare sector. Enhanced diagnostic capabilities, such as genetic testing, have led to earlier and more accurate identification of AIP cases. Furthermore, the pharmaceutical industry is focusing on research and development of novel therapies, while improved patient education is helping to manage symptoms effectively. Despite these advancements, challenges such as underdiagnosis and limited treatment options persist. A collaborative approach among healthcare professionals, researchers, and pharmaceutical companies is essential to navigate the complexities of the AIP market and improve patient outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Acute Intermittent Porphyria market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Acute Intermittent Porphyria Market Segments Analysis

Global Acute Intermittent Porphyria Market is segmented by Diagnosis, Treatment, End Users and region. Based on Diagnosis, the market is segmented into Blood Test, Urine Test, DNA Test and Serum Test. Based on Treatment, the market is segmented into Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions. Based on End Users, the market is segmented into Hospitals, Clinics and Research Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Acute Intermittent Porphyria Market

The increasing emphasis on advanced diagnostic techniques has significantly improved the identification of Acute Intermittent Porphyria (AIP) cases, enabling quicker intervention and more effective management. Furthermore, the development of innovative treatment options, including hematin infusions and novel RNA interference therapies such as givosiran, presents robust strategies for managing acute attacks and providing sustained symptom control. This combination of enhanced detection and evolving therapeutic alternatives is driving the growth of the AIP market, ultimately improving patient outcomes and quality of life for those affected by this rare genetic disorder.

Restraints in the Acute Intermittent Porphyria Market

A significant constraint in the Acute Intermittent Porphyria (AIP) market is the challenge of underdiagnosis, which stems from the condition's rarity and the intricate nature of its symptoms. This complexity often results in delays or even oversight in recognizing those affected by AIP. Furthermore, the limited availability of treatment options compounds this issue, as current therapies primarily focus on managing symptoms rather than providing a definitive cure. This scenario effectively hampers the market's growth potential, as both diagnosis and treatment face considerable hurdles that can impede timely and effective patient care.

Market Trends of the Acute Intermittent Porphyria Market

The Acute Intermittent Porphyria (AIP) market is experiencing significant growth, driven by advancements in genetic testing technologies that enhance the accuracy and timeliness of diagnoses. This trend is complemented by the emergence of innovative treatments such as RNA interference (RNAi) therapies, notably givosiran, which offer a targeted approach to address the genetic underpinnings of AIP. As these testing methodologies and cutting-edge treatments gain traction, they are likely to improve patient outcomes and foster more personalized management strategies. This convergence of diagnostics and therapeutics is expected to propel market expansion and stimulate interest from pharmaceutical companies and investors alike.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis

Global Acute Intermittent Porphyria Market Size by Diagnosis & CAGR (2025-2032)

• Market Overview
• Blood Test
• Urine Test
• DNA Test
• Serum Test

Global Acute Intermittent Porphyria Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Gonadotropin-Releasing Hormone Analogues
• Prophylactic Hematin Infusions

Global Acute Intermittent Porphyria Market Size by End Users & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Research Centers

Global Acute Intermittent Porphyria Market Size & CAGR (2025-2032)

• North America (Diagnosis, Treatment, End Users)
  • US
  • Canada
• Europe (Diagnosis, Treatment, End Users)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diagnosis, Treatment, End Users)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diagnosis, Treatment, End Users)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diagnosis, Treatment, End Users)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Alnylam Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recordati S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMarin Pharmaceutical Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen Pharma (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Clinuvel Pharmaceuticals Ltd (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mayo Clinic Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bachem Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols, S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring Pharmaceuticals (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dicerna Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zambon S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Luitpold Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vifor Pharma (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations